EDAP TMS SA to Announce First Quarter 2022 Financial Results on May 17, 2022

A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology.

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Tuesday, May 10, 2022

Information

Tags:

Company, TMS, Prostate cancer, Laser, Focal, EDAP, ESWL, Google Images, HIFU, Medical imaging

Geotags:

VAULX-EN-VELIN, RHÔNE-ALPES, FR, EUROPE

Organisation:

EDAP TMS S.A.

Summary

Key Points:

A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology.
By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation.
With the addition of the ExactVu Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer.
EDAP TMS also produces and distributes other medical equipment including the Sonolith i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL).

Company to host conference call and webcast on, Wednesday, May 18^that 8:30 am EDT

LYON, France, May 10, 2022 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31^st, 2022 after the markets close on Tuesday, May 17^th, 2022.

An accompanying conference call and webcast will be hosted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, Ryan Rhodes, CEO of EDAP U.S., and François Dietsch, Chief Financial Officer. The call will be held at 8:30am EDT on Wednesday, May 18^th, 2022. Please refer to the information below for conference call dial-in information and webcast registration.

Conference Call & Webcast
Wednesday, May 18^th@ 8:30am Eastern Time
Domestic:        877-451-6152
International: 201-389-0879
Passcode:        13728747
Webcast:        https://viavid.webcasts.com/starthere.jsp?ei=1541898&tp_key=e83b07e195

About EDAP TMS SA

A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit focalone.com, http://www.edap-tms.com, and us.hifu-prostate.com.

Company contact:
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
[email protected]

Investor Contact
John Fraunces
LifeSci Advisors, LLC
212-915-2568
[email protected]